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Using Cell Replication Data in Mathematical
Modeling in Carcinogenesis
by Christopher J. Portier,' Annette Kopp-Schneider,2 and
Claire D. Sherman3
Risk estimation involves the application of quantitative models of dose versus response to
carcinogenicity data. Recent advances in biology, computing, and mathematics have led to the
application of mathematically complicated, mechanistically based models of carcinogenesis to
the estimation of risks. This paper focuses on two aspects of this application, distinguishing
between models using available data and the development of new models to keep pace with
research developments.
Introduction
Using quantitative models to understand and inter-
pret carcinogenesis is a complex and demanding task.
To use models properly requires not only an under-
standing of mathematics and statistics, but also a fun-
damental knowledge ofthe data involved in this model-
ing and a clear picture of the underlying biology that
generated the data. Thus, modeling exercises in this
area constitute a true blending of disciplines. In this
paper, we address some of the problems involved in
modeling carcinogenesis from the point of view of the
quantitative researcher, outlining assumptions neces-
sary to exploit the data and the models, and we
attempt to explain how these assumptions relate to the
underlying biological processes being modeled. In
addition, we give some details concerning alternative
modeling approaches we are investigating and direc-
tions for future research in this area.
With few exceptions, the mathematical modeling of
carcinogenesis has concentrated on the use of multi-
stage models. In the mid-20th century, there were sev-
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eral theoretical discussions ofhow the biological theory
of carcinogenesis might be turned into mathematical
models (1-3). However, the first practical application of
this class ofmodels was done by Armitage and Doll (4).
The Armitage-Doll (AD) model of carcinogenesis is
illustrated in Figure la. The basic concept is that cells
progress from a state in which they display normal cel-
lular function into a malignant state via a fixed number
of stages that must occur in a particular sequence. For
their model to adequately describe cancer data, this
progression generally required between four and seven
stages. Each stage represents an additional critical
mutation in the genome, with the final mutation leading
to the formation of a single malignant cell, which pro-
gresses rapidly to an observable neoplasm. The model
was applied in a variety of contexts, including the
description of early and late-stage carcinogens (5),
design (6,7) and analysis (8) of carcinogenicity experi-
ments, and the estimation oflow-dose cancerrisks (9).
Later, several researchers (10-12) noted one obvious
failure in the theoretical basis of the AD model: it
failed to take into account the growth kinetics of cell
populations. Figure lb illustrates a two-stage model
(TS) of carcinogenesis, which allows for the birth and
death/differentiation of cells. In this model, cells
progress through two stages, normal cells and cells
having one critical mutation, before the ultimate muta-
tion that leads to the formation of malignancies. Each
ofthese types of cells undergoes a birth-death process
that allows the population of cells in a particular stage
to either expand in number through mitosis or to
reduce in numberthrough cell death or terminal differ-
entiation. Originally, the TS model was applied to
tumor incidence data in the same manner as the AD
model (12,13) and proved quite successful in explainingPORTIER ETAL.
results which the AD model failed to describe ade-
quately. In recent years, due to the onset of newer
techniques in toxicology, cell biology, biochemistry,
and other fields, we are able to apply the TS model to a
much broader range ofexperimental data (14,15). With
few exceptions (16), when applied properly, this model
has done an adequate job ofdescribing the experimen-
tal results in the observable range.
Even though the TS model seems to provide an ade-
quate description ofa large class ofdata, the advent of
new information on carcinogenic mechanisms and the
availability offaster computers has led to the creation
of more complicated mathematical models of carcino-
genesis. Figure lc illustrates one such model (17). This
multistage model ofcarcinogenesis expands the process
of cellular mutation into a two-stage process, the first
being movement of a cell from the normal state to a
damaged state due to DNA damage and the second
representing movement from the damaged state to the
initiated state via fixation ofthat DNA damage by cell
mitosis. Note that in this model, unlike the TS model,
there is also repair ofthe DNA damage returning the
damaged cell to the normal state. The major advantage
of this damage/repair multistage model (DR) is that
one can characterize many of the rates of the model
from biochemical data and use the carcinogenicity data
to estimate fewer parameters (18) or, in cases where
all parameters are estimated from biochemical data, to
check the validity ofthe model.
Although it is important that mathematical models be
used to describe existing data, they can serve a much
more useful role by creating a framework in which one
can ask questions about alternative carcinogenic mech-
anisms and define experiments that allow us to answer
these questions. This paper addresses two separate
a. Armitage-Doll Model
StageK
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FIGURE 1. Three different multistage models of carcinogenesis in
which j=mutation rates, ,=birth rates, S=death rates, A DNA
damage rates, and p=DNA repair rates.
issues. The first concerns our ability to distinguish
between the existing models of carcinogenesis, apply-
ing the data commonly available to the mathematical
modeler. This is intended to provide some insight into
the difficult issue of distinguishing between curve-fit-
ting and mechanistic modeling. The second issue con-
cerns the development ofnew models ofcarcinogenesis
as a consequence of data suggesting modifications to
the existing theory. One modification concerns the
presence or absence of stem cells in each stage of the
carcinogenic process. Another modification addresses
the potential for all cells in a given stage ofthe carcino-
genic process to progress to a higher stage These two
issues are fundamental to our understanding ofthe car-
cinogenic process and form the basis forthe mathemati-
cal models that are currently applied to carcinogenicity
data. Alternatives to the default mechanisms used in
this context are discussed.
Mechanistic Modeling of
Carcinogenesis
To understand the difference between true mecha-
nistic modeling and curve fitting, we must begin by
studying the levels of information available for these
exercises. Table 1 illustrates the types of information
available to the researcher in attempting to model car-
cinogenesis. In Table 1 the available data relating to
carcinogenesis are broken into four broad categories:
biochemical data, cellular data, tissue-specific data, and
data on the whole organisms. Under each category,
examples of the types of data one might collect are
given. This list is not intended to be exhaustive but to
simply illustrate how one might view the available
information.
True mechanistic modeling of carcinogenesis would
involve the application of information from the lowest
level (in this case biochemical data) to predict results
at a higher level. For example, in true mechanistic
modeling ofcarcinogenesis, we would use cellular data
Table 1. Examples oflevels ofinformation that are avail-
able for estimating parameters in multistage models of
carcinogenesis.
Biochemical
Gene expression
Protein levels
Receptorbinding
Adduct formation
Cell
Mitosis
Cell death
Tissue
Hyperplasia
Hypertrophy
Carcinogenicity
Chemical distribution/disposition
Improperdevelopment function
Organism
Morbidity
Mortality
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and biochemical data to characterize a carcinogenic
response and only use tissue-specific cancer data to
verify that the model predictions are correct. This has
been described by numerous researchers as a bottom-
up process ofmodeling carcinogenesis.
Curve fitting, on the other hand, generally involves
information obtained at the level for which inference is
desired. In this case, you would have some model that
describes an end point, say, cancer, and you would use
direct information on that end point to estimate the
parameters in this model.
Let us consider an example. Suppose you want to
use a TS model of carcinogenesis to explain the car-
cinogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) in the liver of female rats. True mechanistic
modeling of this effect would involve the creation of a
model for the distribution of TCDD to the tissues in
the rat, the binding ofTCDD to the Ah receptor in the
rat, gene expression for the TCDD-receptor complex,
and ofthe relationship these end points with the muta-
tion rates and birth/death rates in the TS model of car-
cinogenesis. The model would have to be built in
essence from first principals, ignoring the available
tumor incidence data and focusing only on the bio-
chemical and cellular data. After all of these pieces of
the model have been put together, tumor incidence
could be predicted and compared with what was
obtained from whole animal experiments and human
experience. Ifthe model agrees with the data, it can be
used as a working hypothesis of how TCDD leads to
cancer. If it fails, one would attempt to understand
why (at the cellular and biochemical level) and seek
information within the context of the model to correct
the failure.
Alternatively, one could directly fit the TS model to
the carcinogenicity data or mortality data available for
TCDD. In this case, biological confidence in the model
is reduced. This curve-fitting approach is useful for
obtaining working estimates ofthe mutation rates and
birth/death rates that might be studied then at the cel-
lular orbiochemical levels.
In general, neither ofthese two procedures are used
exclusively in modeling carcinogenesis. Instead, a com-
bination approach is generally used in which some
parameters in the model are obtained from cellular and
biochemical experiments, and others are obtained from
the carcinogenicity data. A good example of this
approach is given by Kopp-Schneider and Portier (15).
This combined approach to modeling carcinogenesis
leads to the question ofhow accurately one can charac-
terize an assumed mechanism with the available data.
There are many statistical and biological issues that
have not been addressed in this context. We are
endeavoring to address some of the statistical issues
but currently have few results. However, we have
addressed a similar problem by studying the degree to
which tumor incidence data can be used to characterize
carcinogenic mechanisms. To illustrate the problems
involved in this field, we will discuss some of our find-
ings concerning the estimation of model parameters
and the characterization ofthe best model when using
only tumorincidence data.
Statistical Issues in Model
Discrimination
Statistical methods are routinely used to test for dif-
ferences between various alternatives. For example,
the simple t-test is used to test for the equality of the
means in two treatment groups. Similartechniques can
be used to assess the adequacy of one model for
explaining a set of results as compared to an alterna-
tive model. Kopp-Schneider and Portier (19) consid-
ered the possibility of distinguishing between the AD
model and the TS model (Fig. 1) using only information
on tumor incidence, which is routinely available to
modelers.
We first looked at the fit ofthe two models to the his-
torical control data from recent National Toxicology
Program (NTP) studies of carcinogenicity (16). Table 2
illustrates the results from this analysis. Table 2 pre-
sents the results from fitting the two models to seven
Table 2. Comparison oftwo stage model (TS) andArmitage-Doll model (AD) using National Toxicology Program
historical control data (19).
Female mice Male mice
TSa ADa Stagesb TSa ADa Stagesb
Circulatory system
Hemangioma-hemangiosarcoma - - + + 2-8
Liver
Adenoma/neoplastic nodule + + 2-3 + + 2
Carcinoma + + 2-6 - -
Hematopoietic system
Leukemia/lymphoma - - + + 2-7
Lung
Alveolar/bronchiolar adenoma + + 2-3 + + 2
Aleveolar/bronchiolar carcinoma + . + 2-4 + + 2-8
Both + + 2-3 <2
a(+)Indicates the model fitthe data, (-) indicates a lack offit (standard chi-square goodness-of-fit test atp=O.10level).
bNumber ofstages in the AD model that adequately fit the data.
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tumor sites in male and female B6C3F1 mice. The col-
umn labeled "TS" indicates whether the two-stage
model fit the data (p =0.10), with a + indicating an ade-
quate fit and - indicating lack of fit. Similarly, the AD
column indicates the degree offit forthe Armitage-Doll
model. It is clear from this table that when one model
fits the data, the other also fits. Similarly, when one
model fails tofitthe data, so does the other. Thus, using
goodness of fit as a measure of model correctness, we
are unable to differentiate between these two models
on the basis of tumor incidence data. This is partially
due to the magnitude ofthe variability one sees in the
tumor incidence data and partially due to the flexibility
ofthese models when applied to these data.
As a separate issue, we also considered how many
stages in the AD model were in agreement with the
observed data. In Table 2, the column labeled "stages"
shows that, for most ofthe data sets, multiple numbers
ofstages agreed with the data including cases where a
model with two stages and a model with eight stages
both agreed with the same data (circulatory system
tumors and lung carcinomas in male mice).
The data used in this analysis, were, in some sense,
the best data available because there were over 2000
animals in each data set with a considerable amount of
information on age-specific tumor incidence. To study
this issue for more realistic-size data sets, a simulation
study was performed in which data were generated
from one model, and the ability of the other model to
provide a better fit to the data was assessed. In this
case, experimental situations with fewer animals were
used. The results of this analysis are summarized in
Table 3. The exact cases that were studied are given in
more detail in Kopp-Schneider and Portier (19). The
point to note is that unless the true underlying model
is an AD model with many stages, our chances of dis-
criminating between these two models are dismal.
Dose effects are just as difficult to assess. In recent
research (20,21), we considered the possibility ofdistin-
guishing between treatment effects on mutation rates
and treatment effects on birth rates within the context
of the TS model. We concluded that, with the usual
design of the long-term animal carcinogenicity experi-
ment using chronic dosing, it is unlikely that a unique
effect on either of these two rates could be clearly
Table 3. Comparison oftwo-stage model and Armitage-Doll
model using Monte Carlo simulations (21).
% Simulations in which
wrongmodel yields
Underlying model Description best fit
Armitage Doll 2 stages 48-50
5 stages 15-20
8 stages 17-22
Two-stage Nopromotion 48-50
Little promotion 43-54
Medium promotion 33-57
Higherpromotion 37-58
exhibited (20,21). It was also shown that modifying that
design to include start-stop dosing would help some-
what, but it still did not dramatically improve our abili-
tyto properly characterize treatment effects.
What may prove to be the best way to determine
treatment effects on birth, death, and mutation rates is
to use data that relates directly to these end points.
However, similar problems may also hold for the appli-
cation of models to biochemical data and cellular data.
Portier et al. (22) have demonstrated this fact with two
simple receptor models for the effects ofTCDD on cel-
lular proteins. Similar problems arise with the use of
physiologically based pharmacokinetic models (23). It
is likely that this will also occur with cellular data
because labeling index is a widely varying measure.
Thus, it may be difficult to place any degree of confi-
dence on parameters derived from these data (14),
especially with regard to initiation effects versus pro-
motional effects. This is an area that still requires con-
siderable research.
In short, the toxicological and biological dataroutinely
collected for use in modeling multistage carcinogenesis
leave large gaps in our ability to distinguish between
models. This does not imply that this information should
not be used. On the contrary, we wholeheartedly sup-
port the application of these data in modeling carcino-
genesis. However, extreme caution should be used in
interpreting the resulting model parameters and in
placingconfidence in anypredictions fromthese models.
Alternative Models of
Carcinogenesis
Multistage models of carcinogenesis have become
the de facto standard for modeling carcinogenesis.
Within this class of models, the TS model is perhaps
the most popular among researchers, and the AD
model is the most widely used. However, often the
biologist and the statistician/mathematician are using
similar terminology but discussing quite different
processes. In this section, we carefully outline some of
the assumptions that typically go with the use of the
TS model and discuss alternative models that may
have a more realistic basis in the underlying biology.
In addition, we discuss the role of these alternative
models in studying carcinogenic mechanisms.
The first issue to be considered is the meaning of
stages in multistage carcinogenesis. In mathematical
parlance, stages constitute a sequence of events that
must occur in a prescribed order for the carcinogenic
event to be observed. Thus, in the TS model (Fig. lb),
malignant cells can only arise from initiated cells; there
is only a single pathway to carcinogenesis. However, it
is unlikely that carcinogenesis arises in such a simplis-
tic fashion.
In contrast to multistage carcinogenesis, there is the
forgotten class of multihit models. Hit theories of car-
cinogenesis hypothesize that a normal cell must be
damaged a multiple number of times before it results
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in a malignant cell. There is no implied order to these
hits, thus it is the accumulation of damage that differ-
entiates this theory from multistage theory. Hit theo-
ries have been developed but were generally not
accepted due to the perceived simplistic nature and
lack ofbiological plausibility relative to the TS model.
The fundamental difference between the TS model
and a two-hit model is whether a malignant cell is gen-
erated by a particular sequence of mutations or by
cumulative mutations, where the sequence of muta-
tional events is inconsequential. Thus, the TS model
represents only one possible path to malignancy,
whereas the two-hit model represents all possible
paths to malignancy consisting of two mutational
events. By restricting the order of events, the two-hit
model results in the TS model.
An alternative concept is the fusion ofthe two theo-
ries into a single framework. We refer to this concept
as multipathway/multistage theory. Biological evi-
dence for the multipathway/multistage theory is sup-
ported by current cancer research in the area of onco-
genes and suppressor genes. Oncogenes are thought to
be genes whose activation accelerates cell growth.
Suppressor genes are thought to work in the opposite
manner; they are genes whose deactivation removes
some restrictions on the mechanism that regulates cell
proliferation. Thus, ifoncogenes are activated and sup-
pressor genes deactivated, the net result is believed to
be a cell, and eventually a colony ofcells, with little or
no growth control.
Experimental evidence suggests that at least two
activated oncogenes are necessary for eventual tumor
development (24,25). Oncogene activation may be the
result ofchromosome translocation, gene amplification,
point mutation, or deletions/alterations in the chro-
matin. These activated oncogenes can be classified into
two groups: myc-type oncogenes and ras-type onco-
genes. These two groups of oncogenes complement
each other, resulting in synergistic activity. This
enhanced growth activity is one possible component in
the production ofamalignant cell (26,27).
The number of genetic events necessary to deacti-
vate a tumor-suppressor gene has been conservatively
estimated as two, but may be as many as three or four
depending on the type of cancer (28,29). These lesions
may be the result oflarge-scale deletions or rearrange-
ments ofsegments ofthe chromosomes, inactivation of
gene products, or point mutations. Once oncogenes are
activated and tumor-suppressor genes deactivated,
uncontrolled cell growth generally ensues.
Fearon and Vogelstein (30) state that multiple, dis-
tinct mutations may have to accumulate before a cell
becomes malignant. These genetic changes may occur
in a specific order; however, they indicate the accumu-
lation of changes is most important for malignancy to
occur. This is believed to correspond to the genetic
changes necessary to alterthe expression ofoncogenes
and tumor-suppressor genes. A clear example of the
multipathway/multistage theory of carcinogenesis is
l(1h)
FIGURE 2. A multipath/multistage model ofcarcinogenesis consisting
oftwo stages (initiated cells and malignant cells) and one hit.
illustrated by the work ofVogelstein and others on the
molecular biology of colon cancer (e.g., 30). Careful
characterization of human tumors has shown a mixed
pattern of genetic changes, which is more readily
described by a combination of multiple pathways than
by a strictly multistage process.
The mathematical modeling of carcinogenesis should
proceed in the direction of incorporating hits and
stages within a unified theory. There has been some
development along these lines, but it has been sparse.
Portier (20) examined the effect of multiple two-stage
paths to carcinogenesis, and Tan (21) partially expand-
ed this to a general theory. Much research needs to be
done before it can be routinely used.
To illustrate what might be meant by a multipath/
multistage model, consider the model in Figure 2. This
is a simple two-stage model of carcinogenesis with a
single path added to the first stage. In this model, a
single mutation with rate jl, transforms a cell into an
initiated cell. The rate ,ut depends on the rate ofrepli-
cation, 0, of the population in which the mutation is
occurring. There are two populations from which initi-
ated cells are drawn: the population ofnormal cells [so
that the rate from normal cells to initiated cells is
g1(00)] and anotherpopulation ofhit cells [so the rate of
mutation from hit cells to initiated cells is g9(03)].
These hit cells are the result ofa mutation ofthe normal
cells, which occurs at rate po. They are not necessary to
the carcinogenic process but can contribute to it by
enhancing the chances ofgenerating an initiated cell. As
in the TS model described earlier, a single mutation in
the initiated cellsresults in amalignant cell.
It is possible to approximate a hit/stage model with
the simpler multistage model by allowing for time-
dependent rates and other modifications. We would not
support this approach because the approximation is
likely to be inadequate and could lead to false infer-
ences from the model. This has been observed and dis-
cussed for other multistage models in the context of
tumor incidence modeling (32,33,34), and it is unlikely
that approximations for this class ofmodels will be any
different. Furthermore, it would be far better to match
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the mathematical development to the biology. This not
only limits confusion between the biologists and the
mathematicians, it also allows us to directly exploit bio-
logical data on carcinogenic mechanisms (e.g., DNA
damage rates, DNA repair rates, patterns ofoncogene
expression). In the long run, this will strengthen infer-
ences drawn from the model and result in greater confi-
dence in the utility ofthese models forrisk assessment.
Another potential problem with the current collec-
tion of multistage models of carcinogenesis concerns
the mathematics involved in the process by which
births and deaths are modeled. The process currently
used is a standard birth-death process, which is com-
mon in the area of probability theory (35). As defined
mathematically, this process is questionable as a mech-
anistic descriptor for a biological system, especially for
the growth kinetics of initiated cells. Its shortcomings
are described below.
A stochastic birth-death process works in the follow-
ing fashion. Cells act independently ofall other cells in
the system (this is referred to as a "linear" process).
At random times, based on an exponential distribution,
events occur in these cells. For a simple birth-death
process, these events include the division of one cell
into two cells (birth) and the removal of one cell from
the system (death). Once the time of a cellular event
has been determined, deciding on which event occurs
is similar to flipping a weighted coin where the proba-
bility of heads (birth) is the birth rate divided by the
sum ofthe birth rate and the death rate. The probabili-
ty oftails (death) is 1 minus the probability ofheads.
The first major assumption of concern in these
processes is that cells act independently of each other.
It is a well-established fact that cells communicate and
that there is a homeostatic feedback system that con-
trols the size ofagiven population ofcells. Ingeneral, if
the number of cells in a population is large, the linear
birth-death process is adequate for describing the
kinetics of the system of cells without concern for a
dependence between the cells. However, for smaller
populations of cells, as is possible with initiated cell
populations (e.g., premalignant focal lesions in the liver,
papillomas in the skin), cellular dependencies may play
a major role in the observed growth kinetics. This will
be especially true when modelingpotential carcinogenic
effects due to regenerative hyperplasia, a mechanism
that has been proposed for some compounds. The cur-
rent models of carcinogenesis may not be adequate for
addressing these issues. Time-dependent changes in
the rates for multistage models have been used in this
context, but it is not clear how well this approximation
addresses this interdependence between cells. There
have been some attempts at developing the mathemati-
cal theory necessary to use non-linear models, but this
has proven to be, as yet, untenable. The advent offast,
inexpensive computers has provided some hope for
numerical solutions to allow for the utility of these
models, but, as illustrated in Portier and Kopp-
Schneider (17), an order-of-magnitude increase in com-
puting speed is still necessary to make this approach
trulypractical formodelingcarcinogenesis.
Another concern with the birth-death processes used
in multistage models is the lack of true stem cells in
the model. A true stem cell would have different death
characteristics than other cells in the tissue in that it
would remain for a very long time. In addition, most of
the other cells in the population would be derived from
this stem cell. In addition to stem cells, there are also
likely to be size restrictions on the population of initi-
ated cells where the birth rate and death rate depend
on the size of the clone and limitations on the number
of divisions the progeny of a stem cell are likely to
undergo. These processes, again, differ drastically
from the simple linear birth-death process used in mul-
tistage models.
Another issue relates to the importance ofstem cells
in modeling carcinogenesis. More specifically, the issue
is determining which cells in the premalignant clone
should be considered as initiated cells able to proceed
to malignancy. Moolgavkar et al. (14) and Kopp-
Schneider and Portier (15) analyzed data on the clonal
expansion of premalignant cells in the liver and skin,
respectively, but do not relate their model results to
tumor rates. To relate the findings for colonies of pre-
malignant cells to the incidence of malignancy, one
must make an assumption concerning the proportion of
cells in the clone ofpre-malignant cells that may go on
the malignancy. The usual two-stage model (Fig lb)
allows all cells in the premalignant clones to act as ini-
tiated cells and to go on to malignancy. This is the
model that was used by Moolgavkar et al. Kopp-
Schneider and Portier modified this model to estimate
the number of actively dividing (nonterminally differ-
entiated) cells in the papillomas they were studying
because many of the cells in these papillomas are ter-
minally differentiated and can no longer go on to
malignancy. Some proportion ofthese actively dividing
cells could constitute the initiated cell population with
respect to carcinogenesis. One alternative would be a
stem-cell-based two-stage model in which only a small
percentage of the cells in the initiated cell population
(as few as one) can go on to malignancy. When using
information on the size and number of premalignant
lesions in attempting to model carcinogenicity, this
issue must be handled cautiously. Biologists need to
expand research in this area to improve our knowledge
ofthese processes. (As an aside, it is important to note
that the stem cell has different meanings in biology
and modeling. In the context of the discussion above,
the biological definition is intended.)
Improved handling of stem cells is one area where
mathematical modeling could improve the science of
carcinogenesis. A careful analysis should lead to exper-
imental designs in which the result of the study will
clearly differentiate between a model in which all cells
go on to malignancy and one in which only a few cells
go on to malignancy. One such design is an initiation-
promotion study with two promotion phases separated
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by a period of no exposure. By waiting long enough
between promotion phases, we should be able to get
some handle on the presence orabsence ofstem cells in
the tissue and on the number of initiated cells impor-
tant to the carcinogenic process. Research on this issue
is currently underway.
Discussion
This paper has addressed two specific issues in the
application of mechanistic models to understanding
and evaluating carcinogenic risks. The first issue is the
ability ofthe data currently being collected to provide
us with meaningful estimates of the parameters in
these models. There is little ability to discriminate
between alternative models and mechanisms with the
data that are currently available. A concerted effort is
needed to find novel designs to address the application
of mechanistic models of carcinogenesis. This effort
must be truly interdisciplinary, including mathemati-
cians, statisticians, and biologists working on all
aspects of the carcinogenicity issue. This is especially
important in discriminating between chemically
induced changes in cell proliferation and chemically
induced changes in mutation rates, in determining
whether chemically induced mutations are necessary
(stages) to the carcinogenic process or simply augment
carcinogenesis (hits), and in determining the size and
properties of the critical population of initiated cells
(stem cells versus differentiated cells).
The second issue is basically a mathematical one: the
development and application of more realistic models
relating to the proliferation of cells. The current mod-
els do not truly characterize the biology as it is
observed and understood. This could lead to bias in our
interpretation of the analytical results and incorrect
estimates of carcinogenic risks derived from the mod-
els. There needs to be additional research into the
development of more realistic models and additional
research into the limitations, if any, of current models
fordealing with more complex carcinogenicity data.
One final issue should be noted. In an interdiscipli-
nary field such as mechanistic modeling of carcinogen-
esis, it is vitally important that the model being used
be described exactly and that all parties involved in
applying the model have a working knowledge of its
limitations and assumptions. Thus, biologists will have
to spend a bit oftime trying to understand the mathe-
matical assumptions and properties of the models and
mathematicians/statisticians will have to get better
acquainted with the data they are addressing. Only in
this way can the field move forward and true mecha-
nistic modeling ofcarcinogenesis be achieved.
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